Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis (PsOsim)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis
Sponsor: Coherus Oncology, Inc.
A PHASE3 clinical study on Plaque Psoriasis, this trial is completed. The trial is conducted by Coherus Oncology, Inc. and has accumulated 14 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
14 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 9 earlier versions
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
-
May 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Mar 2020 — May 2020 [monthly]
Completed PHASE3
-
Nov 2019 — Mar 2020 [monthly]
Completed PHASE3
-
Jun 2018 — Nov 2019 [monthly]
Completed PHASE3
-
Apr 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2017 — Apr 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Aug 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Coherus Oncology, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Afula, Israel , Ancona, Italy , Anderson, United States , Arlington, United States , Barnaul, Russia , Bialystok, Poland , Bristol, United States , Cary, United States , Charlotte, United States , Chisinau, Moldova and 74 more locations